Renal denervation for the treatment of resistant hypertension: Review and clinical perspective

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 7, 2015, Pages F583-F594

  Iliescu, Radu ^a   Lohmeier, Thomas E ^b   Tudorancea, Ionut ^a   Laffin, Luke ^c   Bakris, George L ^c  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Denervation; Hypertension; Pathophysiology; Renal nerves; Resistance

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; META ANALYSIS; NERVE CONDUCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SYMPATHETIC NERVE; SYMPATHETIC TONE; DENERVATION; DRUG RESISTANCE; HYPERTENSION, RENAL; KIDNEY; KIDNEY CIRCULATION; PROCEDURES; SYMPATHECTOMY;

DENERVATION; DRUG RESISTANCE; HUMANS; HYPERTENSION, RENAL; KIDNEY; RENAL CIRCULATION; SYMPATHECTOMY;

EID: 84943276026     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00246.2015     Document Type: Article

References (87)

1. Alnima T, de Leeuw PW, Tan FE, Kroon AA. Renal responses to long-term carotid baroreflex activation therapy in patients with drugresistant hypertension. Hypertension 61: 1334-1339, 2013.
2. Armitage JA, Burke SL, Prior LJ, Barzel B, Eikelis N, Lim K, Head GA. Rapid onset of renal sympathetic nerve activation in rabbits fed a high-fat diet. Hypertension 60: 163-171, 2012.
3. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375: 1173-1181, 2010.
4. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370: 1393-1401, 2014.
5. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3: 486-492, 2007.
6. Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, May CN. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 65: 393-400, 2015.
7. Booth LC, Schlaich MP, Nishi EE, Yao ST, Xu J, Ramchandra R, Lambert GW, May CN. Short-term effects of catheter-based renal denervation on cardiac sympathetic drive and cardiac baroreflex function in heart failure. Int J Cardiol 190: 220-226, 2015.
8. 1-receptor antagonism reverses the blood pressure elevation associated with dietinduced obesity. Am J Physiol Regul Integr Comp Physiol 289: R181-R186, 2005.
9. Bravo EL, Tarazi RC, Dustan HP, Fouad FM. The sympathetic nervous system and hypertension in primary aldosteronism. Hypertension 7: 90-96, 1985.
10. Briasoulis A, Bakris G. Renal denervation after SYMPLICITY HTN-3: where do we go? Can J Cardiol 31: 642-648, 2015.
11. Briasoulis A, Bakris GL. Timing and efficacy of alternative methods of sympathetic blockade. Curr Hypertens Rep 14: 455-461, 2012.
12. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 60: 1485-1490, 2012.
13. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51: 1403-1419, 2008.
14. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, and American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117: e510-e526, 2008.
15. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49: 839-845, 2007.
16. Cowley AW Jr. Long-term control of arterial blood pressure. Physiol Rev 72: 231-300, 1992.
17. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 77: 75-197, 1997.
18. Dorresteijn JA, Schrover IM, Visseren FL, Scheffer PG, Oey PL, Danser AH, Spiering W. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 31: 393-403, 2013.
19. Dzielak DJ, Norman RA Jr. Renal nerves are not necessary for onset or maintenance of DOC-salt hypertension in rats. Am J Physiol Heart Circ Physiol 249: H945-H949, 1985.
20. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124: 1046-1058, 2011.
21. Esler M. Renal denervation for hypertension: observations and predictions of a founder. Eur Heart J 35: 1178-1185, 2014.
22. Esler M. The sympathetic nervous system in hypertension: back to the future? Curr Hypertens Rep 17: 11, 2015.
23. Fu Q, Zhang R, Witkowski S, Arbab-Zadeh A, Prasad A, Okazaki K, Levine BD. Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity? Hypertension 45: 513-521, 2005.
24. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 168: 1159-1164, 2008.
25. Goldblatt H, Gross J, Hanzal RF. Studies on experimental hypertension. II. The effect of resection of splanchnic nerves on experimental renal hypertension. J Exp Med 65: 233-241, 1937.
26. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res 116: 976-990, 2015.
27. Grassi G, Seravalle G, Brambilla G, Pini C, Alimento M, Facchetti R, Spaziani D, Cuspidi C, Mancia G. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol 177: 1020-1025, 2014.
28. Guyton AC. Arterial Pressure and Hypertension. Philadelphia, PA: Saunders, 1980.
29. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesityinduced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 116: 991-1006, 2015.
30. Hall JE, Guyton AC, Smith MJ Jr,. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol Renal Fluid Electrolyte Physiol 239: F271-F280, 1980.
31. Hart EC, McBryde FD, Burchell AE, Ratcliffe LE, Stewart LQ, Baumbach A, Nightingale A, Paton JF. Translational examination of changes in baroreflex function after renal denervation in hypertensive rats and humans. Hypertension 62: 533-541, 2013.
32. Henegar JR, Zhang Y, De Rama R, Hata C, Hall ME, Hall JE. Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs. Am J Hypertens 27: 1285-1292, 2014.
33. Henegar JR, Zhang Y, Hata C, Narciso I, Hall ME, Hall JE. Catheterbased radiofrequency renal denervation: location effects on renal norepinephrine. Am J Hypertens 28: 909-914. 2015.
34. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 61: 457-464, 2013.
35. Hildebrandt DA, Irwin ED, Cates AW, Lohmeier TE. Regulation of renin secretion and arterial pressure during prolonged baroreflex activation: influence of salt intake. Hypertension 64: 604-609, 2014.
36. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 44: 847-852, 2004.
37. Iliescu R, Irwin ED, Georgakopoulos D, Lohmeier TE. Renal responses to chronic suppression of central sympathetic outflow. Hypertension 60: 749-756, 2012.
38. Jacob F, Ariza P, Osborn JW. Renal denervation chronically lowers arterial pressure independent of dietary sodium intake in normal rats. Am J Physiol Heart Circ Physiol 284: H2302-H2310, 2003.
39. Judy WV, Watanabe AM, Henry DP, Besch HR Jr,. Sympathetic nerve activity: role in regulation of blood pressure in the spontaneously hypertensive rat. Circ Res 38: 21-29, 1976.
40. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O’Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 36: 219-227, 2015.
41. Kline RL. Renal nerves and experimental hypertension: evidence and controversy. Can J Physiol Pharmacol 65: 1540-1547, 1987.
42. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol 238: R353-R358, 1980.
43. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: 1275-1281, 2009.
44. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383: 622-629, 2014.
45. Le Fevre ME, Guild SJ, Ramchandra R, Barrett CJ, Malpas SC. Role of angiotensin II in the neural control of renal function. Hypertension 41: 583-591, 2003.
46. Leon LA, McKinley MJ, McAllen RM, May CN. Aldosterone acts on the kidney, not the brain, to cause mineralocorticoid hypertension in sheep. J Hypertens 20: 1203-1208, 2002.
47. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-1913, 2002.
48. Lohmeier TE, Dwyer TM, Hildebrandt DA, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension 46: 1194-1200, 2005.
49. Lohmeier TE, Dwyer TM, Irwin ED, Rossing MA, Kieval RS. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 49: 1307-1314, 2007.
50. Lohmeier TE, Iliescu R. The baroreflex as a long-term controller of arterial pressure. Physiology (Bethesda) 30: 148-158, 2015.
51. Lohmeier TE, Iliescu R. Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation. J Appl Physiol 113: 1652-1658, 2012.
52. Lohmeier TE, Iliescu R. The sympathetic nervous system in obesity hypertension. Curr Hypertens Rep 15: 409-416, 2013.
53. Lohmeier TE, Iliescu R, Dwyer TM, Irwin ED, Cates AW, Rossing MA. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol 299: H402-H409, 2010.
54. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 59: 331-338, 2012.
55. Lohmeier TE, Liu B, Hildebrandt DA, Cates AW, Georgakopoulos D, Irwin ED. Global-and renal-specific sympathoinhibition in aldosterone hypertension. Hypertension 65: 1223-1230, 2015.
56. Masuo K, Rakugi H, Ogihara T, Esler MD, Lambert GW. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 6: 58-67, 2010.
57. Matsukawa T, Miyamoto T. Does infusion of ANG II increase muscle sympathetic nerve activity in patients with primary aldosteronism? Am J Physiol Regul Integr Comp Physiol 294: R1873-R1879, 2008.
58. Melder RJ, Tunev S, Ruwart J, Coates P, Trudel J, Schulz-Jander D, Rothman M. Preclinical insights into the optimal ablation location for renal denervation procedures. J Am Coll Cardiol 64, Suppl: B67, 2014.
59. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 17: 1057-1062, 1991.
60. Mogil RA, Itskovitz HD, Russell JH, Murphy JJ. Renal innervation and renin activity in salt metabolism and hypertension. Am J Physiol 216: 693-697, 1969.
61. Moranne O, Bakris G, Fafin C, Favre G, Pradier C, Esnault VL. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol 8: 1694-1701, 2013.
62. Mulder J, Hokfelt T, Knuepfer MM, Kopp UC. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol 304: R675-R682, 2013.
63. Norman RA Jr, Dzielak DJ. Role of renal nerves in onset and maintenance of spontaneous hypertension. Am J Physiol Heart Circ Physiol 243: H284-H288, 1982.
64. Norman RA Jr, Murphy WR, Dzielak DJ, Khraibi AA, Carroll RG. Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension 6: 622-626, 1984.
65. Oparil S, Wyss JM, Sripairojhikoon W. The role of renal nerves in the pathogenesis of hypertension. In: Reflex Control of the Circulation, Zucker IH and Gilmore JP. Boca Raton, FL: CRC, 1991, p. 451-491.
66. Page IH. The relationship of the existing renal nerves to the origin of experimental hypertension. Am J Physiol 112: 166-171, 1935.
67. Page IH, Heuer GJ. The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension. J Clin Invest 14: 27-30, 1935.
68. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 57: 1076-1080, 2011.
69. Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A, Severino F, Rosa J, Adiyaman A, Fadl Elmula FE, Taylor A, Pechere-Bertschi A, Wuerzner G, Jokhaji F, Kahan T, Renkin J, Monge M, Widimsky P, Jacobs L, Burnier M, Mark PB, Kjeldsen SE, Andersson B, Sapoval M, Staessen JA. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 28: 150-156, 2014.
70. Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, Blicher MK, Severino F, Wuerzner G, Taylor A, Pechere-Bertschi A, Jokhaji F, Fadl Elmula FE, Rosa J, Czarnecka D, Ehret G, Kahan T, Renkin J, Widimsky J Jr, Jacobs L, Spiering W, Burnier M, Mark PB, Menne J, Olsen MH, Blankestijn PJ, Kjeldsen S, Bots ML, Staessen JA. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 63: 1319-1325, 2014.
71. Reinhart GA, Lohmeier TE. Role of the renin-angiotensin system in mediating the effects of posture on renal function. Am J Physiol Regul Integr Comp Physiol 271: R282-R288, 1996.
72. Reinhart GA, Lohmeier TE, Hord CE Jr. Hypertension induced by chronic renal adrenergic stimulation is angiotensin dependent. Hypertension 25: 940-949, 1995.
73. Robles RG, Villa E, Santirso R, Martinez J, Ruilope LM, Cuesta C, Sancho JM. Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. Am J Hypertens 6: 1009-1015, 1993.
74. Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, Bednar F, Zelinka T, Holaj R, Strauch B, Somloova Z, Taborsky M, Vaclavik J, Kocianova E, Branny M, Nykl I, Jiravsky O, Widimsky J Jr. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: sixmonth results from the Prague-15 study. Hypertension 65: 407-413, 2015.
75. Sakakura K, Tunev S, Yahagi K, O’Brien AJ, Ladich E, Kolodgie FD, Melder RJ, Joner M, Virmani R. Comparison of histopathologic analysis following renal sympathetic denervation over multiple time points. Circ Cardiovasc Interv 8: e001813, 2015.
76. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension-its identification and epidemiology. Nat Rev Nephrol 9: 51-58, 2013.
77. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361: 932-934, 2009.
78. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1, 266 cases. J Am Med Assoc 152: 1501-1504, 1953.
79. Symplicity HTN Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57: 911-917, 2011.
80. Symplicity HTN Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376: 1903-1909, 2010.
81. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 286: F8-F15, 2004.
82. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57: 1069-1075, 2011.
83. Van Vliet BN, Smith MJ, Guyton AC. Time course of renal responses to greater splanchnic nerve stimulation. Am J Physiol Regul Integr Comp Physiol 260: R894-R905, 1991.
84. Verloop WL, Spiering W, Vink EE, Beeftink MM, Blankestijn PJ, Doevendans PA, Voskuil M. Denervation of the renal arteries in metabolic syndrome: the DREAMS-study. Hypertension 65: 751-757, 2015.
85. Vink EE, Verloop WL, Siddiqi L, van Schelven LJ, Liam Oey P, Blankestijn PJ. The effect of percutaneous renal denervation on muscle sympathetic nerve activity in hypertensive patients. Int J Cardiol 176: 8-12, 2014.
86. Winternitz SR, Katholi RE, Oparil S. Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat. J Clin Invest 66: 971-978, 1980.
87. Zappe DH, Capel WT, Keen HL, Shek EW, Brands MW, Hall JE. Role of renal afferent nerves in obesity-induced hypertension. Am J Hypertens 9: 20A, 1996.